Literature DB >> 12041952

Management of skin disease in patients with lupus erythematosus.

Jeffrey P Callen1.   

Abstract

Skin disease in patients with lupus erythematosus may be subdivided into two broad categories - those represented by a 'specific' histopathology, the interface dermatitis, and those with changes that are not specific to lupus erythematosus, for example, vasculitis, mucin infiltration, etc. The specific skin lesions that are most common are discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE). Evaluation will allow the treating physician to assign a prognosis. Cutaneous lesions can generally be managed with standard therapies. Patients with discoid LE and subacute cutaneous LE are generally photosensitive, and therefore sunscreens, protective clothing and behavioural alteration should be discussed with all patients. Topical corticosteroids are a standard form of therapy, but 'newer' agents such as retinoids, calcipotriene and tacrolimus might be effective. Antimalarial agents are generally effective. Attempts to reduce or stop smoking may aid in the control of cutaneous LE. The choice of alternative therapy is personal, and discussions of the risks and benefits should be carefully documented. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12041952     DOI: 10.1053/berh.2001.0224

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  5 in total

1.  Prognosis of patients with systemic lupus erythematosus and discoid lesions.

Authors:  Thelma Larocca Skare; Bárbara Stadler; Emilio Weingraber; Diogo F De Paula
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

Review 2.  Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.

Authors:  Joshua Chang; Victoria P Werth
Journal:  Expert Rev Clin Immunol       Date:  2016-06-01       Impact factor: 4.473

Review 3.  Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.

Authors:  Kristen L Chen; Rebecca L Krain; Victoria P Werth
Journal:  F1000Res       Date:  2019-03-25

4.  A case of lupus erythematosus profundus with severe ulceration that responded to tumor necrosis factor-alpha--blocking agents.

Authors:  Daiki Nakagomi
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007

5.  Interventions for cutaneous disease in systemic lupus erythematosus.

Authors:  Cora W Hannon; Collette McCourt; Hermenio C Lima; Suephy Chen; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2021-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.